Ablavar Related Published Studies
Well-designed clinical trials related to Ablavar (Gadofosveset)
Contrast-enhanced whole-heart MR coronary angiography at 3.0 T using the intravascular contrast agent gadofosveset. [2009.07]
Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study. [2008.01]
Other research related to Ablavar (Gadofosveset)
Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium. [2011.02]
CMR assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset. [2011.01.26]
Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment. [2011.01]
Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: Multicenter intraindividual crossover comparison. [2010.08]
Contrast-enhanced whole-heart coronary MRA using Gadofosveset 3.0 T versus 1.5 T. [2010.07]
Gadofosveset-enhanced magnetic resonance imaging of human carotid atherosclerotic plaques: a proof-of-concept study. [2010.05]
First-pass and steady-state magnetic resonance angiography of the thoracic vasculature using gadofosveset trisodium. [2009.10]
Thoracic and abdominal MRA with gadofosveset: influence of injection rate on vessel signal and image quality. [2009.08]
Gadofosveset-enhanced MR angiography of carotid arteries: does steady-state imaging improve accuracy of first-pass imaging? Comparison with selective digital subtraction angiography. [2009.05]
A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease. [2008.02]
Gadofosveset-enhanced magnetic resonance angiography. [2008]
Whole-heart coronary magnetic resonance angiography with MS-325 (Gadofosveset). [2007.11]
Other possibly related research studies
High Spatial Resolution and High Contrast Visualization of Brain Arteries and Veins: Impact of Blood Pool Contrast Agent and Water-Selective Excitation Imaging at 3T. [2010.08.27]
Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. [2010.03]
[Nephrogenic systemic fibrosis] [2009.10]
Increased volume of coverage for abdominal contrast-enhanced MR angiography with two-dimensional autocalibrating parallel imaging: initial experience at 3.0 Tesla. [2009.11]
Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. [2010.01]
MR angiographic follow-up of intracranial aneurysms treated with detachable coils: evaluation of a blood-pool contrast medium. [2009.09]
Dynamic magnetic resonance angiography of the arteries of the hand. A comparison between an extracellular and an intravascular contrast agent. [2009.02]
Intravascular contrast agent T1 shortening: fast T1 relaxometry in a carotid volunteer study. [2008.09]
Current status of renal artery magnetic resonance imaging: theoretical and practical considerations and the potential role of blood-pool contrast agents. [2007.03]
Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model. [2007.07]
Imaging the whole body atherosclerosis: high resolution magnetic resonance angiography using blood-pool agent. Initial clinical experience. [2007.06]
[Diagnostic performance of contrast-enhanced MR angiography of the aortoiliac arteries with the blood pool agent Vasovist: initial results in comparison to intra-arterial DSA] [2007.04]
Combined respiratory and cardiac triggering improves blood pool contrast-enhanced pediatric cardiovascular MRI. [2011.12]
High-resolution MRI of carotid plaque with a neurovascular coil and contrast-enhanced MR angiography: one-stop shopping for the comprehensive assessment of carotid atherosclerosis. [2011.05]
Morphological and functional 3-Tesla magnetic resonance imaging of saphenous vein coronary artery bypass grafts. [2011.04]
Imaging patients with kidney disease: how do we approach contrast-related toxicity? [2011.03]
High spatial resolution and high contrast visualization of brain arteries and veins: impact of blood pool contrast agent and water-selective excitation imaging at 3T. [2010.12]
Combined magnetic resonance imaging of deep venous thrombosis and pulmonary arteries after a single injection of a blood pool contrast agent. [2011.02]
Diagnosis of popliteal venous entrapment syndrome by magnetic resonance imaging using blood-pool contrast agents. [2011.02]
|
